dc.contributor
Institut Català de la Salut
dc.contributor
[Liu MC] Divisions of Allergy and Clinical Immunology, Pulmonary and Critical Care Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA. [Chipps B] Capital Allergy and Respiratory Disease Center, Sacramento, CA, USA. [Munoz X] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Ciber Enfermedades Respiratorias, Madrid, Spain. [Devouassoux G] Service de Pneumologie, Hôpital de la Croix Rousse, Hospices Civils de Lyon, UCB Lyon, Lyon, France. [Bergna M] Respiratory Research, CEMER, Vicente Lopez, Buenos Aires, Argentina. [Smith SG] Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Liu, Mark C.
dc.contributor.author
Chipps, Bradley
dc.contributor.author
Devouassoux, Gilles
dc.contributor.author
Bergna, Miguel
dc.contributor.author
Smith, Steven G.
dc.contributor.author
Muñoz, Xavier
dc.date.accessioned
2025-10-24T10:35:29Z
dc.date.available
2025-10-24T10:35:29Z
dc.date.issued
2022-01-13T17:33:32Z
dc.date.issued
2022-01-13T17:33:32Z
dc.date.issued
2021-05-10
dc.identifier
Liu MC, Chipps B, Munoz X, Devouassoux G, Bergna M, Smith SG, et al. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics. Respir Res. 2021 May 10;22:144.
dc.identifier
https://hdl.handle.net/11351/6793
dc.identifier
10.1186/s12931-021-01733-9
dc.identifier
000656440500002
dc.identifier.uri
https://hdl.handle.net/11351/6793
dc.description.abstract
Asma; Tractament de l'asma; Eosinòfils
dc.description.abstract
Asma; Tratamiento del asma; Eosinófilos
dc.description.abstract
Asthma; Asthma treatment; Eosinophils
dc.description.abstract
Background
The OSMO study assessed the efficacy of switching to mepolizumab in patients with severe eosinophilic asthma that was uncontrolled whilst receiving omalizumab. The objective of this analysis was to assess the proportion of patients achieving pre-defined improvements in up to four efficacy outcomes and the relationship between patient baseline characteristics and treatment response.
Methods
This was a post hoc analysis of OSMO study data (GSK ID:204471; ClinicalTrials.gov No. NCT02654145). Patients with severe eosinophilic asthma uncontrolled by high-dose inhaled corticosteroids, other controller(s) and omalizumab subcutaneously (≥ 4 months) were switched to mepolizumab 100 mg administered subcutaneously. Endpoints included the proportion of responders—i.e. patients achieving a pre-defined clinical improvement in ≥ 1 of the following outcomes: (1) Asthma Control Questionnaire (ACQ)-5 score (≥ 0.5-points), (2) St George’s Respiratory Questionnaire (SGRQ) total score (≥ 4-points), (3) pre-bronchodilator forced expiratory volume in 1s (FEV1; ≥ 100 mL), all at Week 32, and (4) annualised rate of clinically significant exacerbations (≥ 50% reduction).
Results
Of the 145 patients included, 94%, 83%, 63% and 31% were responders for ≥ 1, ≥ 2, ≥ 3 and 4 outcomes, respectively; 75% and 78% were ACQ-5 and SGRQ score responders, and 50% and 69% were FEV1 and exacerbation responders. Subgroup analyses demonstrated improvements irrespective of baseline blood eosinophil count, prior omalizumab treatment regimen/duration, comorbidities, prior exacerbation history, maintenance oral corticosteroid use, ACQ-5 and SGRQ scores, and body weight/body mass index.
Conclusions
After switching to mepolizumab, almost all patients with uncontrolled severe eosinophilic asthma on omalizumab achieved a beneficial response in ≥ 1 clinical outcome. Improvements were observed regardless of baseline characteristics.
dc.description.abstract
This post hoc analysis and the parent study (GSK ID: 204471; ClinicalTrials.gov number: NCT02654145) were funded by GSK.
dc.format
application/pdf
dc.format
application/pdf
dc.relation
Respiratory Research;22
dc.relation
https://doi.org/10.1186/s12931-021-01733-9
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Asma - Tractament
dc.subject
Avaluació de resultats (Assistència sanitària)
dc.subject
DISEASES::Respiratory Tract Diseases::Lung Diseases::Pulmonary Eosinophilia
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Drug Prescriptions::Drug Substitution
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome
dc.subject
ENFERMEDADES::enfermedades respiratorias::enfermedades pulmonares::eosinofilia pulmonar
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::prescripciones de medicamentos::sustitución de medicamentos
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
dc.title
Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
